Home › Funds › PSP Research LLC › RAPP

PSP Research LLC position in RAPP

RAPT THERAPEUTICS INC · Health Care

PSP Research LLC reported holding 14,000 shares of RAPP (RAPT THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$583K, representing 0.31% of its reported portfolio and ranking #8 among its reported holdings. PSP Research LLC has disclosed RAPP holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

Latest position (Q2 2026)14.00K sh
Reported value held$583.38K
Portfolio Weight0.31%
First reportedQ4 2025
Last changeNew

How PSP Research LLC's RAPP position evolved

PSP Research LLC first disclosed a stake in RAPP in Q4 2025 at 17,506 shares (US$531K). The position peaked in Q2 2026 at 14,000 shares, worth US$583K. Across 3 filings, PSP Research LLC increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 14,000 shares valued at US$583K.

Quarter by quarter

QuarterSharesValueChange
Q4 2025 17.51K $531.13K New
Q1 2026 14.00K $438.06K Reduce
Q2 2026 14.00K $583.38K New

Dots on the line are colored by change type; missing quarters mean no position was reported.

About RAPP and 13F data

RAPP (RAPT THERAPEUTICS INC) is a Health Care company. 67 other funds we track also report a position in RAPP — the largest reported positions include TRV GP V, LLC (US$261.7M), ARCH Venture Management, LLC (US$155.4M), Cormorant Asset Management, LP (US$110.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding RAPP

All RAPP fund holders →